We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About GE HealthCare (GEHC) Q2 Earnings
Read MoreHide Full Article
In its upcoming report, GE HealthCare Technologies (GEHC - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.04 per share, reflecting a decline of 1.9% compared to the same period last year. Revenues are forecasted to be $5.27 billion, representing a year-over-year increase of 5.3%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain GE HealthCare metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenues- Imaging' will reach $2.34 billion. The estimate indicates a change of +6.2% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- AVS (Advanced Visualization Solutions)' reaching $1.35 billion. The estimate points to a change of +4.7% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Other' will reach $12.94 million. The estimate indicates a change of +115.7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- PDx (Pharmaceutical Diagnostics)' of $802.08 million. The estimate points to a change of +10% from the year-ago quarter.
Analysts forecast 'Revenues- PCS (Patient Care Solutions)' to reach $760.31 million. The estimate suggests a change of -2.3% year over year.
Shares of GE HealthCare have experienced a change of -6% in the past month compared to the +1.7% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), GEHC is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About GE HealthCare (GEHC) Q2 Earnings
In its upcoming report, GE HealthCare Technologies (GEHC - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.04 per share, reflecting a decline of 1.9% compared to the same period last year. Revenues are forecasted to be $5.27 billion, representing a year-over-year increase of 5.3%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain GE HealthCare metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenues- Imaging' will reach $2.34 billion. The estimate indicates a change of +6.2% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- AVS (Advanced Visualization Solutions)' reaching $1.35 billion. The estimate points to a change of +4.7% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Other' will reach $12.94 million. The estimate indicates a change of +115.7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- PDx (Pharmaceutical Diagnostics)' of $802.08 million. The estimate points to a change of +10% from the year-ago quarter.
Analysts forecast 'Revenues- PCS (Patient Care Solutions)' to reach $760.31 million. The estimate suggests a change of -2.3% year over year.
View all Key Company Metrics for GE HealthCare here>>>Shares of GE HealthCare have experienced a change of -6% in the past month compared to the +1.7% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), GEHC is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .